# A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct07255872/  
OnCo record `nct07255872` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Cytarabine, Daunorubicin, Venetoclax and Azacitidine in acute myeloid leukaemia, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia is a phase 2/3 interventional study registered as NCT07255872 by Sichuan Baili Pharmaceutical Co., Ltd., with 216 participants planned, started 2026-04-02 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M11D1, Cytarabine, Daunorubicin, Venetoclax and Azacitidine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07255872
- Phase: 2/3
- Setting: A Phase II/III Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M11D1 for Injection in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 216

## Sources

- ClinicalTrials.gov NCT07255872: https://clinicaltrials.gov/study/NCT07255872

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Daunorubicin](https://onco.cc/drugs/daunorubicin/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07255872.json